Canopy’s first-in-class Antigen-Drug Conjugates (AgDCs) target the root cause of antibody-mediated autoimmunity, replacing chronic immunosuppression with disease-modifying, symptom-free remission.
Canopy’s AgDCs are designed to selectively target the <0.01% of autoantibodies and rare B-cell clones that drive autoimmunity while preserving 99.99% of protective immunity, aiming to address the root cause of antibody-mediated autoimmune diseases without chronic immunosuppression.
Canopy creates precision, antigen-specific therapies to target the root cause of autoimmune diseases while preserving protective immunity. Replacing chronic immunosuppression with targeted immune editing, our approach aims to deliver durable, disease-modifying remission across multiple antibody-mediated conditions.
Canopy’s platform combines an inhibitory Fc scaffold and advanced payload conjugation with interchangeable antigenic domains to target disease-driving autoantibodies and B-cells. This modular design allows rapid expansion across autoimmune diseases, led by MGAC-007 as a potential new standard of care.
Canopy is led by an experienced founder-CEO, supported by a world-class Board and Advisory, including Chairman Dr. Cedric François (APLS), Board Member John Cox (DYN), leading biotech investors, non-clinical ex-biopharma advisory, and clinical KOLs with vast experience advancing new therapeutic towards the clinic.
Scientific milestones, platform validation, and clinical-readiness updates
Canopy’s first-in-class Antigen-Drug Conjugates (AgDCs) are designed to redefine treatment of antibody-mediated autoimmune diseases by replacing chronic immunosuppression with targeted immune reprogramming aimed at durable, disease-modifying, symptom-free remission.
